Most of that deficit represents funding from accredited investors in Oncolix over several years as private company.
It represents the amount of funding that was used for Prolanta R&D, preclinical trials and transition to FDA phase one human clinical trials, as well as establishing a worldwide patent portfolio of over 30 patents relating to Cancer treatment.
It is the sweat equity and heavy lifting that had been done prior to ONCX becoming a public company.
Anyone claiming that the deficit here is a red flag, is either intentionally posting misleading information or ignorant of the facts.
Wrong, they have several options in regards of refinancing and repaying that debt.
The very term Accredited Investment includes high net worth individuals who are capable of investing from their own homes. It is common for some investors to be successful enough to work from home. The concept is obviously alien to some.
False. The original recruitment was completed and patients were dosed in 2016.
ONCX is currently dosing the second group of participants in phase one FDA clinical trials.
False, most of the executive compensation has been deferred. ONCX Officers have received a fraction of the compensation owed to them and none of the board members have received shares for simply serving on the board.
The ONCX BOD are uncompensated at this time with the exception of John W. Holaday, who filed a disclosure statement with the SEC showing that he hasn’t received any shares as some falsely claim.
As the only compensated ONCX board member he is receiving $1000 per month if I remember correctly.